COL4A5

The COL4A5 gene encodes the alpha-5 chain of type IV collagen, a crucial structural protein in the basement membranes of the kidneys, inner ear, and eyes. 

Mutations in COL4A5 are the primary cause of X-linked Alport syndrome (XLAS), a hereditary disorder that leads to progressive kidney disease, hearing loss, and ocular abnormalities, making genetic testing essential for diagnosis, prognosis, and early intervention.

What is COL4A5 (Collagen Type IV Alpha 5 Chain)?

The COL4A5 gene encodes the alpha-5 chain, one of the six subunits of type IV collagen, a critical component of the basement membrane in tissues such as the kidneys, inner ears, and eyes. 

Mutations in COL4A5 are the primary cause of X-linked Alport syndrome (XLAS), a hereditary disorder that leads to progressive kidney disease, hearing loss, and eye abnormalities. 

This gene, located on the X chromosome, spans 51 exons and is involved in forming the α345(IV) collagen network in the glomerular basement membrane (GBM), which supports kidney function.

Mutations in COL4A5 can be truncating (leading to a more severe phenotype with earlier onset of end-stage renal disease [ESRD]) or non-truncating (associated with later onset and slower disease progression). 

Truncating mutations generally cause ESRD to develop by the second decade of life, while non-truncating mutations lead to a later median age of ESRD onset (around 39 years). 

These mutations also influence other clinical manifestations such as hearing loss and ocular changes.

Genetic analysis of COL4A5 mutations is a diagnostic requirement and informs the prognosis for XLAS. This gene's mutations are functionally assessed using various diagnostic methods, including immunohistochemistry to detect the absence of α5(IV) in skin biopsies. 

Additionally, functional assays can assess the impact of missense mutations on collagen assembly, revealing how mutations affect trimer formation and secretion, correlating with clinical severity.

RAAS inhibitors like ACE inhibitors and ARBs have been shown to delay ESRD onset in XLAS patients, with the effect being more pronounced in those with non-truncating mutations. 

Early and long-term use of these medications can significantly reduce the risk of progression to ESRD, with each additional 6 months of treatment reducing this risk by 7%. These findings underline the importance of genetic testing to guide early intervention and improve patient outcomes in XLAS.

Disorders Associated with COL4A5 Mutations

The following condition is associated with COL4A5 mutations:

X-Linked Alport Syndrome

X-linked Alport syndrome (XLAS) is a genetic disorder caused by mutations in the COL4A5 gene. This gene encodes the alpha-5 chain of type IV collagen, a critical component of the kidney's glomerular basement membrane. 

XLAS primarily affects males and leads to progressive kidney disease, sensorineural hearing loss, and eye abnormalities. Hematuria (blood in urine) is an early sign of Alport syndrome.

The severity of the condition can vary depending on the type of mutation. Truncating mutations often result in early-onset end-stage renal disease (ESRD) by the second decade of life, while non-truncating mutations generally lead to a later onset of ESRD, with a median age of onset of around 39 years. 

Early clinical signs include hematuria, followed by proteinuria, hypertension, and a gradual decline in kidney function. Genetic testing is essential for diagnosis, and treatment focuses on managing proteinuria and delaying ESRD progression.

Who Should Get COL4A5 Genetic Testing?

Genetic testing for COL4A5 is indicated for individuals with a history of hematuria (blood in the urine), especially if there is a family history of kidney disease, hearing loss, or eye problems. 

This includes:

Individuals With Suspected Alport Syndrome

Testing is essential to confirm a diagnosis of Alport syndrome and determine the inheritance pattern.

Family Members of Those With COL4A5 Mutations

Genetic testing for family members can assess carrier status and evaluate the risk of passing the mutation to future generations.

Genetic counseling is strongly recommended before and after testing, as COL4A5 mutations have varying inheritance patterns and clinical presentations.

What Do Specific COL4A5 Mutations Mean?

Identifying a pathogenic mutation in the COL4A5 gene confirms a diagnosis of Alport syndrome. The location and type of mutation (missense, deletion, etc.) can help predict the severity of the disease and the specific inheritance pattern. 

X-linked mutations tend to cause more severe disease in males, while females with one copy of the mutation (carriers) may have milder symptoms, such as hematuria, or may be asymptomatic.

Test Procedure and Interpretation

The following section outlines the testing procedures and interpretation.

Testing Procedure and Preparation

Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types. 

A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.

Normal Reference Ranges

Normal reference ranges for COL4A5 genetic testing are considered to be without mutations that can alter the activity of the COL4A5 proteins.

Clinical Implications of Positive COL4A5 Mutations

The clinical implications of a positive COL4A5 mutation test result will vary by individual, although COL4A5 mutations in symptomatic patients may signal a need for further assessment and possibly treatment, especially in the setting of kidney symptoms.

Patients or practitioners with questions about the clinical implications of COL4A5 mutations should seek further assessment with a genetic counselor or expert. 

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.